<DOC>
	<DOCNO>NCT00401830</DOCNO>
	<brief_summary>This trial investigate efficacy safety 400mg/day lacosamide compare placebo reduce sign symptom fibromyalgia syndrome .</brief_summary>
	<brief_title>Assessing Efficacy Safety Lacosamide Compared Placebo Reducing Signs Symptoms Fibromyalgia Syndrome .</brief_title>
	<detailed_description>This proof-of-concept study power statistical comparison . The trial consist 4-week Titration Phase , 8-week Maintenance Phase , 1-week Taper Phase , 2-week Safety Follow-Up Phase . If subject meet eligibility criterion , randomize receive either lacosamide 400mg/day placebo Maintenance Phase . Subjects assign lacosamide titrate 100mg/day 400mg/day weekly interval 100mg . All subject complete 4-week Titration Phase enter 8-week Maintenance Phase . No dose adjustment allow Maintenance Phase . The Treatment Phase define combined Titration Maintenance Phases .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Males female , 18 65 year old Fulfills 3 point American College Rheumatology ( ACR ) definition diagnosis fibromyalgia At least moderate pain ( pain intensity ≥ 5 Likert pain scale ( 010 ) 7 day prior Baseline ) Fibromyalgia Impact Questionnaire ( FIQ ) total score ≥ 50 Completed adequate washout period exclude medication prior begin Baseline Diary Phase Symptomatic regional structural rheumatic disease Diagnosed neuropathic pain syndrome Receiving treatment neurostimulating device Significant psychopathology History chronic alcohol drug abuse within 6 month prior Screening Been hospitalize psychiatric behavioral reason within 6 month prior Screening Clinically significant abnormal vitals , cardiac dysfunction /or arrhythmias Taken neuroleptic , serotonin norepinephrine reuptake inhibitor ( SNRIs ) tricyclic antidepressant ( TCAs ) Other medical condition could compromise subject 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Fibromyalgia Syndrome</keyword>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>Harkoseride</keyword>
</DOC>